

IT'S TIME TO ACT

ON OBESITY & TYPE 2 DIABETES

Overweight and obesity is estimated to be a contributory factor in up to

80%
of T2D cases²



Almost 30% of the world's population is overweight or obese.¹

Diabetes can lead to serious complications including:³



heart disease



stroke



blindness



kidney disease



amputations

DID YOU KNOW?

There are an estimated **64 million diabetes sufferers** in the European region alone⁴



And in 2015, there were **627,000 deaths** attributed to diabetes in Europe⁵


OBESITY AND T2D ARE A SERIOUS BURDEN TO HEALTHCARE SYSTEMS

Medical costs associated with treating obese patients can be up to **30%** greater




than for normal weight patients⁶

Estimates indicate that diabetes was responsible for **9%** of total health expenditure in the Europe region for 2015⁷



CURRENT MEASURES AREN'T ENOUGH

Only **20%** of obese patients on dietary treatment maintain a weight loss of $\geq 10\%$ after three years⁸



No country has successfully decreased obesity rates in **33 years**⁹



TIME TO ACT ON EFFECTIVE TREATMENT OPTIONS

Metabolic surgery is associated with higher diabetes remission rates, lowered mortality risk, fewer complications, higher weight loss and improved quality of life¹⁰⁻¹⁵



DID YOU KNOW?

The Diabetes Surgery Summit (DSS) II Guidelines, recommends:

- Metabolic Surgery for patients with T2D who had a BMI ≥ 40 regardless of glycemic control or a BMI ≥ 35 with inadequately controlled hyperglycemia.
- Consideration of metabolic surgery for patients with T2D with a BMI 30–34.9 with inadequately controlled hyperglycaemia.¹⁶



Evidence shows that surgery is clinically and cost effective¹⁷⁻²¹



Yet less than **2%** of eligible patients are treated in countries with the highest metabolic surgery uptake, per year²²

So far... the DSS-II guidelines have been endorsed by

45

medical and scientific societies worldwide¹⁶



IT'S TIME TO TAKE CONTROL. IT'S TIME TO ACT.

Johnson & Johnson

MEDICAL
DEVICES
COMPANIES